Information for Connecticut Prescribers
Provided Pursuant to Connecticut H.B. 6669

Under Connecticut law, prescription drug manufacturers are required to disclose in writing to Connecticut prescribers the list price of marketed drugs when engaging in prescription drug marketing, promotion, or in the provision of information regarding a legend drug for human use. This disclosure provides the list price in the form of the wholesale acquisition cost ("WAC") for the product(s) listed below.

Regeneron is providing OTARMENI® (lunsotogene parvec-cwha) at no cost to treat clinically eligible individuals in the United States.

For more information on access, contact Regeneron's OnPath with OTARMENI® (lunsotogene parvec-cwha) patient support program at 1-866-500-GENE (1-866-500-4363).

Pricing as of 04/24/2026